Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2002;3 Suppl 1(Suppl 1):S26-33.
doi: 10.1186/rr187.

Immunoprophylaxis of respiratory syncytial virus: global experience

Eric A F Simoes  1
Affiliations
Review

Immunoprophylaxis of respiratory syncytial virus: global experience

Eric A F Simoes. Respir Res. 2002.

Abstract

Respiratory syncytial virus (RSV) infects nearly all children by age 2 years, and it causes considerable illness and death in certain high-risk pediatric populations. Historically, treatment for RSV has been symptomatic, and developing a safe and effective vaccine has been a challenge. Therefore, research efforts have turned to passive immunization as the best option to control RSV. Palivizumab, a genetically engineered humanized monoclonal antibody, has been shown to reduce RSV-related hospitalizations significantly, with few adverse effects. It was approved for use in high-risk children in the USA in 1998 and in Europe in 1999; it is now approved for use in more than 45 countries. The efficacy and safety of palivizumab continue to be supported by both clinical trial and outcomes data.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Weighted mean hospitalization rates due to RSV (standard deviation indicated by vertical bars) in children ≤ 2 years old with BPD/CLD, in infants at 29–32 weeks' gestational age (wGA) without CLD, and in infants at 32–35 wGA without CLD (combined analysis). Data from Simoes [44].
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Sigurs N, Bjarnason R, Sigurbergsson F, Kjellman B. Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Am J Respir Crit Care Med. 2000;161:1501–1507. - PubMed
    1. Stein RT, Sherrill D, Morgan WJ, Holberg CJ, Halonen M, Taussig LM, Wright AL, Martinez FD. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet. 1999;354:541–545. doi: 10.1016/S0140-6736(98)10321-5. - DOI - PubMed
    1. Weber MW, Milligan P, Giadom B, Pate MA, Kwara A, Sadiq AD. Respiratory illness after severe respiratory syncytial virus disease in infancy in The Gambia. J Pediatr. 1999;135:683–688. doi: 10.1016/S0022-3476(99)70085-5. - DOI - PubMed
    1. Centers for Disease Control and Prevention Respiratory syncytial virus activity: United States, 1999–2000 season. MMWR Morb Mortal Wkly Rep. 2000;49:1091–1093. - PubMed
    1. Heilman CA, from the National Institute of Allergy andInfectious Diseases and the World Health Organization Respiratory syncytial and parainfluenza viruses. J Infect Dis. 1990;161:402–406. - PubMed

MeSH terms